Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases

$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV

Immunocore Limited, the world’s leading TCR company developing biological drugs to treat cancer, infectious diseases and autoimmune diseases, today announced an investment from the Bill & Melinda Gates Foundation to support the development of Immunocore’s soluble TCR-based therapeutics for infectious diseases.